Effective at the market close on Thursday October 22, 2020, IMMU will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights.
On September 13, 2020, Immunomedics agreed to be acquired by Gilead Sciences for $88.00 per share in cash.
